

Index

abscess, pelvic, 53–4	batch tracing, 79	controlled ovarian stimulation (COS), 10. <i>See also</i> maturation trigger injection
accessibility, ovary, 43, 46–7	benzodiazepines	current monitoring practices for, 10–12
accreditation, supplier, 80–1	conscious sedation and analgesia	conventional IVF (cIVF), 103
accuracy, laboratory procedure, 73	with, 25, 30	failure of, 103–4
admissions lounge, 18–19	nurse administration of, 32	oocyte preparation for, 98, 102, 105–6
adnexal pathology, 50	birefringence, ZP, 90–1	corpus luteum, 8
air quality	bladder, ovarian access and, 46	corticosteroids, progesterone level control with, 12
laboratory, 21, 68–70, 78–9	blastocyst transfer, 112–13	COS. <i>See</i> controlled ovarian stimulation
for oocyte preparation, 98–9	bleeding	COVID-19 pandemic, 74–5
theatre space, 21	after OR, 15–16, 52–3	culture medium, 72
alfentanil, 30, 32, 46–50	during OR, 43–4, 46–8	for oocyte preparation, 98–102
anaesthesia, 24. <i>See also</i> conscious	vaginal, 48, 52	selection of, 78
sedation and analgesia	blood clots, COC, 102–3	temperature of, 77–8
nurse role in, 59	body mass index (BMI)	cumulus expansion, 8
patient perspective of, 109	OR approach and, 15	cumulus-oocyte complex (COC), 8, 65–6
anaesthetic machine, 22	trigger injection dose and, 13	cIVF insemination technique for, 105–6
anaesthetic room, 19	bowel injury, 54–5	culture medium for, 98–102
analgesia, 24. <i>See also</i> conscious	buserelin, 14	denudation of, 105–6
sedation and analgesia		identification of, 73, 98–100
androgens, 4–6	calibration, equipment, 77–8	insemination timing for, 104–5
androstenediol, 4–6	centrally located granular cytoplasm	patient identity and record keeping for, 105
androstenedione, 4–6	(CLGC), 86–7	pipettes used for transfer of, 100–1
aneuploidy	chlorhexidine, vaginal disinfection	transport of, 102–3
oocyte handling and, 65	with, 20	washing of, 98–100
oocyte morphology and, 86–8, 94	cIVF. <i>See</i> conventional IVF	cysts
oocyte temperature and, 20–1	CLGC. <i>See</i> centrally located granular	infection risk in patients with, 53–4
antibiotic prophylaxis, 39, 50, 53–4, 60	cytoplasm	OR in patients with, 39, 42–3, 48, 50
anticoagulation therapy, 52–3	coagulopathy, 52–3	cytoplasmic abnormalities, 85
antral follicles, development of, 4	COC. <i>See</i> cumulus-oocyte complex	centrally located granular cytoplasm, 86–7
morphological changes, 4	co-codamol, 31	diffused granularity, 85–6
oocyte development, 6	colour Doppler, ovarian stimulation	morphological appearance, 85–6
steroidogenesis and atresia, 4–6	monitoring with, 12	refractile bodies, 87
anxiolysis, 24. <i>See also</i> conscious	competency, operator, 81	SERCs, 88–90
sedation and analgesia	conscious sedation and analgesia, 24–35	vacuoles, 87–8
aromatase, 4–6	excessive pain and, 46–50	
asepsis, 62	fasting guidelines for, 25	dark cytoplasm, 85–6
aspiration needle, 20–2	medications for, 31	deep sedation, 24
insertion and removal of, 39–42,	monitoring and oxygenation during, 31	dehydroepiandrosterone (DHEA), 4–6
46–9	nurse role in, 59	
problems with, 46–9	nurse-led, 33–5	
selection of, 40	OHSS considerations and, 31	
aspiration pump, 22, 40, 46–9	patient perspective of, 109	
aspiration tubing, 20, 22, 40	post-sedation care for, 31	
flushing of, 41	pre-operative assessment for, 24–6	
problems with, 46–9	consent. <i>See</i> informed consent	
atresia	consumables. <i>See</i> equipment and consumables	
of antral follicles, 4–6	controlled drugs, 60	
of preantral follicles, 3–4		
audit, 82–4		

- denudation, of cumulus-corona cells, 105–6
 DHEA. *See* dehydroepiandrosterone
 DHT. *See* dihydrotestosterone
 diabetes, 25
 diclofenac, 30–1
 diffused cytoplasmic granularity, 85–6
 dignity, patient, 110
 dihydrotestosterone (DHT), 4–6
 discharge care, 63
 discoloration, ZP, 91
 dish, for oocyte preparation, 98–100
 disinfection, vaginal, 20, 39, 53–4
 documentation, 81–3, 105
 dual-trigger, 14
 dysmorphic ZP, 90–1
- Earls balanced salt solution (EBSS), 101–2
 egg donors, 113
 electronic witnessing, 80
 embryo development, progesterone effects on, 11–12
 embryo grading, 112
 embryo quality
 blastocyst transfer decisions and, 112–13
 follicular flushing effects on, 40–1
 oocyte morphology correlation with, 86–94
 patient confusion over, 112
 trigger injection timing and, 12
 embryo transfer, 112–13
 embryologist
 KPIs for, 82
 training and competence of, 81
 emergency equipment and medicines pack, 60
 empty follicle syndrome, 46–9
 endometrial receptivity, 11–12
 endometrioma, 39, 42–3, 50, 53–4
 endometrium, OR scanning of, 42
 environment
 laboratory, 68, 70, 78–9
 ovarian reserve and, 2–3
 theatre space, 21
 EQR. *See* equipment qualification review
 equipment and consumables
 laboratory, 65–6, 68–9, 74
 consumable and reagent requirements, 72
 monitoring and maintenance of, 70–1
 workstation optimisation, 69–70
 reprotoxicity testing of, 71, 79
 selection of, 78
 OR theatre, 20, 22
 failure of, 46–9
 nurse care of, 59–60, 62
 preparation of, 37, 39–40
 sterilisation of, 38–9, 62
 validation of, 70–1, 77–8
 equipment qualification review (EQR), 77–8
 ESHRE. *See* European Society of Human Reproduction and Embryology
 ethanol, 78–9
 European Society of Human Reproduction and Embryology (ESHRE), QMS guidelines of, 76
 extracytoplasmic anomalies, 90
 discoloration of ZP, 91
 dysmorphic ZP, 90–1
 first polar body morphology, 92–3
 large PVS, 92
 PVS debris, 93–4
 shape anomalies, 91–2
- failure
 OR, 15–16, 44, 46–9
 equipment, 46–9, 71
 fertilisation, 103–4
 fasting guidelines, 25
 fentanyl, 46–50
 fertilisation failure, 103–4. *See also* oocyte quality
 patient perspective on, 112
 fertility preservation
 care of patients undergoing, 61
 patient perspective on, 113
 fibroids, 15
 first polar body morphology, 92–3
 flumazenil, 25
 flushing
 aspiration tubing system, 41
 follicular, 40–2, 61
 follicle
 aspiration of, 39–42, 46–9
 development of, 7
 antral, 4–6
 ovulatory, 6–8
 preantral, 3–4
 primordial, 2–3
 empty, 46–9
 formation of, 2
 monitoring of stimulation of, 10, 16
 historical methods of, 10
 hormonal, 10–12
 OR timing and, 12–13
 transvaginal ultrasonography, 10–11
 trigger injection administration criteria and, 12
 follicle stimulating hormone (FSH), 3–6
 follicular fluid
 nurse care for, 61
 test tubes for, 20–1, 40
 follicular flushing, 40–2, 61
 FSH. *See* follicle stimulating hormone
 FSH receptors (FSHR), 4–6
- gamete traceability system, 38, 60, 80, 105, 109–10
 general anaesthesia, 24
 genetic disorders
 oocyte dysmorphism and, 86–90, 94
 oocyte handling and, 65
 oocyte temperature and, 20–1
 genetic variation, ovarian reserve and, 2–3
 germ cells. *See also* oocyte
 sex determination and early differentiation of, 1–2
 germinal vesicle, 2–3
 germinal vesicle breakdown (GVBD), 8
 GnRH-a. *See* gonadotropin-releasing hormone agonists
 gonadal ridges, 1–2
 gonadotrophin stimulation. *See* ovarian stimulation
 gonadotrophins, antral follicle regulation by, 4–6
 gonadotropin-releasing hormone agonists (GnRH-a), 13–14, 46–9
 gonads, sex determination and early development of, 1–2
 granulations, oocyte cytoplasm, 85–7
 granulosa cells
 of antral follicles, 4–6
 of ovulatory follicle, 6–8
 of preantral follicles, 3–4
 GVBD. *See* germinal vesicle breakdown
- haemoperitoneum, 52–3
 haemorrhage. *See* bleeding
 hand hygiene, 62
 handicapped accessible facilities, 18–19
 hCG. *See* human chorionic gonadotropin
 Health Care Support Workers (HCSW), 58. *See also* nurse
 heated stage
 for oocyte preparation, 98–9
 validation of, 77–8
 hepatitis, laboratory considerations for patients with, 73–4
 HFEA. *See* Human Fertilisation and Embryology Authority
 high insemination concentration (HIC), 103
 HIV. *See* human immunodeficiency virus
 hormonal monitoring, of ovarian stimulation, 10–12

Index

- human chorionic gonadotropin (hCG), 12–14, 46–9
- Human Fertilisation and Embryology Authority (HFEA)
 COVID-19 requirements of, 74–5
 laboratory compliance with Code of Practice of
 consumable and reagent considerations, 72
 design considerations, 67–8, 78–9
 equipment considerations, 71
 patient support policy requirement of, 113
 QMS stipulation of, 76, 82
- human immunodeficiency virus (HIV), laboratory considerations for patients with, 73–4
- hyaluronidase, 105–6
- hydrosalpinx, 42, 50
- ICSI. *See* intracytoplasmic sperm injection
- identification
 cumulus-oocyte complex, 73, 98–100
 patient and gamete, 38, 60, 80, 105, 109–10
- iHFG. *See* International Health Facility Guidelines
- iliac vessels, 43–4, 47–8, 52–5
- in vitro fertilisation (IVF). *See also* conventional IVF; transport IVF
 oocyte quality for, 66
 progesterone level effects on, 11–12
- in vitro maturation (IVM), 42
- incidental adnexal pathology, 50
- incubation, between oocyte collection and insemination, 102, 104–5
- incubator, selection of, 78
- infection, 15–16
 antibiotic prophylaxis for, 39, 50, 53–4, 60
 nurse role in prevention and management of, 62
 risk and mechanisms of, 53–4
 theatre space control measures for, 18–19, 62
 vaginal disinfection for, 20, 39, 53–4
- informed consent, 15–16, 37–8
- inhibins, 6
- insemination. *See also* intracytoplasmic sperm injection
 cIVF technique for, 105–6
 failure of, 103–4
 incubation period before, 102
 selection of technique used for, 103–4
 timing of, 104–5
- installation and operational qualification (IOQ), 77–8
- International Health Facility Guidelines (iHFG), theatre space recommendations of, 19
- International Organisation for Standardisation (ISO), QMS certification of, 76
- intra-abdominal bleeding, 48, 52–3
- intracytoplasmic sperm injection (ICSI), 65, 103
 for fertilisation failure, 103–4
 oocyte preparation for, 98, 102, 106
 assessment of oocyte quality, 106
 denudation of cumulus-corona cells, 105–6
 oocytes selection for, 106
 CLGC, 86–7
 dysmorphic ZP, 90–1
 first polar body morphology, 92–3
 SERCs, 88–90
 timing of, 104–5
- intra-peritoneal bleeding, 52–3
- intrauterine insemination (IUI), rescue, 44
- IOQ. *See* installation and operational qualification
- ISO. *See* International Organisation for Standardisation
- isopropyl alcohol, 78–9
- IUI. *See* intrauterine insemination
- IVF. *See* in vitro fertilisation
- IVM. *See* in vitro maturation
- key performance indicators (KPIs), 82
- kisspeptin, 14
- KPIs. *See* key performance indicators
- laboratory
 air quality of, 21, 68–70, 78–9
 COVID-19 considerations for, 74–5
 design considerations for, 65–7, 74
 environmental, 68, 70, 78–9
 process and personnel flow, 67–8
 equipment and consumables for, 65–6, 68–9, 74
 consumable and reagent requirements, 72
 monitoring and maintenance of, 70–1
 workstation optimisation, 69–70
- OCC identification in, 73
- procedural considerations, 65–6, 73–4
- OR procedure synergism with, 66
- transport IVF arrangement considerations for, 74
- virus positive patient considerations for, 73–4
- laboratory forms, 81–3
- LA-IVF. *See* laser assisted IVF
- laparoscopic oocyte retrieval, 43, 47, 52
- laser assisted IVF (LA-IVF), 103
- leuprolide, 14
- LH. *See* luteinising hormone
- LH receptors (LHR), 4–6
- light exposure, oocyte protection against, 20–1, 68
- lipofuscin inclusions, oocyte, 87
- low back pain, 55
- low molecular weight heparin, 15
- luteinising hormone (LH). *See also* maturation trigger injection
 antral follicle regulation by, 4–6
 corpus luteum support by, 8
 surge, 6, 8
- male partner, pressure experienced by, 110
- maturation promoting factor (MPF), 6, 8
- maturation trigger injection
 confirmation of, 37
 criteria for administration of, 12
 empty follicle syndrome and, 46–9
 insemination timing after, 104–5
 OR timing after, 12–13, 37
 type of agent used in, 13–14
- MEA. *See* mouse embryo assay
- meiosis, germ cells, 2, 8
- meiotic spindle, 8
 depolymerisation of, 20–1, 65
 examination of, 92–3
- menopause, 2–3
- mesonephric duct. *See* Wolffian duct
- microbes, air quality and, 69–70, 78–9
- midazolam
 conscious sedation and analgesia with, 25, 30
 nurse administration of, 32
- monitoring
 of conscious sedation and analgesia, 31
 of laboratory equipment and consumables, 70–1
 of ovarian stimulation, 10, 16
 historical methods of, 10
 hormonal methods of, 10–12
 informed consent considerations, 15–16
 pre-operative assessment for OR, 15
 OR timing, 12–13
 trigger injection administration criteria, 12
 trigger injection maturation agents, 13–14
 ultrasonography methods of, 10–11
- performance, 82–4
- of vital signs, 61–3

- morphology, oocyte, 85, 94
 cytoplasmic abnormalities, 85–90
 extracytoplasmic anomalies, 90–4
 future directions in, 94–5
 mouse embryo assay (MEA), 71, 79
 MPF. *See* maturation promoting factor
 Mullerian agenesis, 47
 Mullerian duct, 1–2
- naloxone, 30
 National Early Warning Score (NEWS)
 chart, 61–3
 National Health Service (NHS), theatre
 space guidance of, 19
 needle. *See* aspiration needle
 needle guide, 21, 39–40
 NEWS chart. *See* National Early
 Warning Score chart
 NHS. *See* National Health Service
 non-steroidal anti-inflammatory drugs
 (NSAIDs), 30–1
 normal saline, vaginal disinfection
 with, 20, 39
 NSAIDs. *See* non-steroidal anti-
 inflammatory drugs
 nurse, OR roles of, 58, 63
 assessment of patient well being,
 61–2
 complication prevention and
 management, 62–3
 documented procedure
 responsibilities, 59
 fertility preservation patient care,
 61
 post-operative care, 62–3
 pre-discharge care, 63
 pre-procedure checklists, 59–60
 pre-procedure planning care, 58–9
 resuscitation equipment check, 60
 retrieval process participation, 61
 sedation care, 59
 sperm sample care, 59
 transgender patient care, 60–1
 WHO surgical pathway
 responsibilities, 59–60
 nurse-led conscious sedation, 31–2
 challenges of, 35
 clinical service evaluation for,
 32–5
 sedation and analgesia protocols for,
 32–4
 training for, 32
 Nursing and Midwifery Council Code,
 core values of, 58
 Nursing Associates, 58. *See also* nurse
- OCC. *See* cumulus-oocyte complex
 oestradiol
 antral follicle production of, 4–6
 ovarian stimulation monitoring of,
 10, 12
 OHSS. *See* ovarian hyperstimulation
 syndrome
 oocyte
 follicular development and
 antral, 4–6
 ovulatory, 6–8
 preantral, 3–4
 primordial, 2–3
 meiosis of, 2, 8
 post-birth *de novo* synthesis of, 2
 oocyte maturation. *See* maturation
 trigger injection
 oocyte preparation
 for cIVF, 98, 102, 105–6
 culture medium for, 98–102
 dish type for, 98–100
 for ICSI, 98, 102, 106
 assessment of oocyte quality, 106
 denudation of cumulus-corona
 cells, 105–6
 initial, 98–9
 insemination technique selection,
 103–4
 insemination timing, 104–5
 patient identity and record keeping,
 105
 pipette use in, 100–1
 transport IVF lessons for, 102–3
 oocyte quality, 66, 85, 94, 106
 cytoplasmic abnormalities and, 85
 centrally located granular
 cytoplasm, 86–7
 morphological appearance, 85–6
 refractile bodies, 87
 SERCs, 88–90
 vacuoles, 87–8
 extracytoplasmic anomalies and, 90
 debris in PVS, 93–4
 discoloration of ZP, 91
 dysmorphic ZP, 90–1
 first polar body morphology, 92–3
 large PVS, 92
 shape anomalies, 91–2
 future directions in, 94–5
 oocyte retrieval (OR). *See also specific
 topics*
 challenges during, 46
 aspiration pump failure, 46–9
 bleeding complications, 46–8
 difficult ovarian access, 43, 46–7
 empty follicle syndrome, 46–9
 excessive pain, 46–50
 incidental adnexal pathology, 50
 complications of, 52, 55–6
 good practice points for
 minimisation of, 55
 haemorrhage, 15–16, 52–3
 nurse role in prevention and
 management of, 62–3
 pelvic infection, 53–4
 pelvic structure injury, 54–5
 vertebral injury, 55
 failure of, 15–16, 44, 46–9
 informed consent for, 15–16, 37–8
 laboratory synergism with, 66
 maturation agents for, 13–14
 patient information for, 58–9, 108
 practical clinical aspects of, 37
 antibiotic prophylaxis, 39, 50,
 53–4, 60
 aspiration needle selection, 40
 bleeding during retrieval, 43–4,
 46–8
 checklist before start, 41, 59–60
 difficult ovarian access, 43, 46–7
 endometrioma considerations, 39,
 42–3
 follicular flushing, 40–2, 61
 in vitro maturation
 considerations, 42
 patient identification, 38, 60, 80
 patient perspective considerations,
 38
 patient positioning, 19–21, 39
 patient review and consent, 37–8
 post-procedure considerations, 44,
 62–3
 preparation for procedure, 37
 scheduling, 37
 sterilisation, 38–9, 62
 surgical technique, 39–42
 temperature control, 20–2, 40,
 65
 tubing system flushing, 41
 ultrasound scan machine
 preparation, 39–40
 vaginal preparation, 20, 39, 53–4
 pre-operative assessment for, 15,
 24–6, 55
 pre-procedure care for, 58–9
 timing of, 12–13, 37
 trigger injection administration for,
 12, 37
 for virus positive patients, 73–4
 workstation optimisation for, 69–70
 oocyte-cumulus-complex. *See*
 cumulus-oocyte complex
 oogonia, 1–2
 oogonial stem cells, 2
 operating theatre. *See* theatre space
 operator, training and competence of,
 81
 opioids, 30, 32
 OR. *See* oocyte retrieval
 osteomyelitis, vertebral, 55
 ovarian artery, 43–4

Index

- ovarian hyperstimulation syndrome (OHSS)
 analgesia for patients with, 31
 hCG trigger injection in risk of, 13–14
 monitoring of, 10, 16
 patient perspective on, 111–12
 post-procedure reassessment of, 44
 ovarian reserve, 2–3
 ovarian stimulation. *See also*
 maturation trigger injection
 monitoring of, 10, 16
 historical methods of, 10
 hormonal methods of, 10–12
 informed consent considerations, 15–16
 pre-operative assessment for OR, 15
 OR timing, 12–13
 trigger injection administration criteria, 12
 trigger injection maturation agents, 13–14
 ultrasonography methods of, 10–11
 SERCs occurrence and, 88–90
 ovary
 difficult access to, 43, 46–7
 early development of, 1–2
 functions of, 1, 8–9
 corpus luteum, 8
 follicle development, 3, 5–8
 follicle formation, 2
 ovoid oocytes, 91–2
 ovulation, 8
 premature, 12–13, 48
 ovulation trigger. *See* maturation trigger injection
 ovulatory follicle, development of, 6
 cumulus expansion, 8
 ovulation, 8
 resumption of meiosis, 8
 oxygenation, for conscious sedation, 31
 pain
 after OR, 15–16, 31
 during OR, 46–50, 109
 low back, 55
 pain management. *See* conscious sedation and analgesia
 paracetamol, 31
 paramesonephric duct. *See* Mullerian duct
 particles, air quality and, 69–70, 78–9
 patient
 identification of
 for OR, 38, 60, 80, 105, 109–10
 for sperm samples, 59, 109–10
 perspectives and experiences of, 108, 113
 anxiety while waiting for egg collection, 108–9
 anxiety while waiting for results, 112
 blastocyst transfer decisions, 112–13
 delivery of poor results, 111
 dignity concerns, 110
 egg calling during collection, 111
 egg donors, 113
 embryo grading confusion, 112
 fertility preservation circumstances, 113
 information on OR, 58–9, 108
 loss of control concerns, 109–10
 male partner pressure, 110
 pain concerns, 109
 post-retrieval side effects, 111–12
 OR staff consideration of, 38
 positioning of, 19–21, 39
 pre-procedure planning communication with, 58–9
 safety of, 58–9, 62–3
 well being of, 61–2
 pelvic abscess, 53–4
 pelvic endometriosis, 39
 pelvic infection. *See* infection
 pelvic inflammatory disease (PID), 53–4
 pelvic structure injury, 54–5
 performance monitoring, 82–4
 perivitelline space (PVS)
 debris in, 93–4
 large, 92
 personal protective equipment, 62
 personnel flow, in laboratory, 67–8
 petri dish, for oocyte preparation, 98–100
 PGCs. *See* primordial germ cells
 pH, oocyte, 72, 98–100
 PID. *See* pelvic inflammatory disease
 pipette
 for denudation, 105–6
 for oocyte preparation, 100–1
 POI. *See* premature ovarian insufficiency
 polycystic ovaries, 10–11
 positive pressure cascade, in laboratory, 68
 post-operative care, 44, 62–3
 post-retrieval side effects, 111–12
 post-sedation care, 31
 povidone iodine, vaginal disinfection with, 20, 39
 preantral follicles, 3–4
 precision, of laboratory procedures, 73
 pre-discharge care, 63
 pregnenolone, 4–6
 pre-granulosa cells, 1–3
 premature ovarian insufficiency (POI), 2–3
 premature ovulation, 12–13, 48
 pre-operative assessment, 15
 for conscious sedation and analgesia, 24–6
 for potential complications, 55
 preovulatory follicle. *See* ovulatory follicle
 pre-procedure checklists, 41, 59–60
 pre-procedure planning, 58–9
 pressure, aspiration, 22, 40, 46–9
 primordial follicles
 activation of, 2–3
 formation of, 2
 primordial germ cells (PGCs), 1–2
 procedure room, 19–21
 process validation, 82
 progesterone
 antral follicle production of, 4–6
 corpus luteum support by, 8
 ovarian stimulation monitoring of, 11–12
 in ovulation, 8
 propofol
 conscious sedation and analgesia with, 25–30
 nurse administration of, 32
 PVS. *See* perivitelline space
 QA. *See* quality assurance
 QC. *See* quality control
 QI. *See* quality improvement
 QMS. *See* quality management system
 quality assurance (QA), 76–7
 quality control (QC), 76–7
 quality improvement (QI), 76–7
 quality management system (QMS), 76–7, 84
 documentation, 81–3
 equipment, media and consumable selection, 78
 laboratory conditions, 78–9
 operator training and competence, 81
 performance monitoring, 82–4
 process validation, 82
 reprotoxicity, 79
 risk assessment, 79–80
 supplier accreditation, 80–1
 temperature control and equipment validation, 77–8
 traceability and witnessing, 80
 reagents, laboratory, 72
 recombinant hCG (r-hCG), 13–14

- record keeping. *See* documentation
- recovery
 post-sedation care during, 31
 space for, 18–19
- refractile bodies, 87
- Registered Midwives, 58. *See also* nurse
- Registered Nurses, 58. *See also* nurse
- reprotoxicity testing, of laboratory
 consumables, 71, 79
- respiratory depression, sedation and
 analgesia causing, 25, 30, 32
- resuscitation equipment, 60
- retinoic acid, 2
- retroperitoneal bleeding, 52–3
- r-hCG. *See* recombinant hCG
- risk assessment, for quality
 management, 79–80
- safety brief, 37
- scheduling, OR, 37
- sedation, 24. *See also* conscious
 sedation and analgesia
- SERCs. *See* smooth endoplasmic
 reticulum clusters
- sex determination, ovarian
 development and, 1–2
- sex-determining region on the
 Y chromosome (*SRY*) gene, 1–2
- shape anomalies, oocyte, 91–2
- sharps, use and disposal of, 62
- smooth endoplasmic reticulum clusters
 (SERCs), 88–90
- somatic cells
 gonadal, 1–2
 re-programming of non-ovarian, 2
- SOPs. *See* standard operating
 procedures
- SOX9 expression, 1–2
- sperm sample
 identification of, 59, 109–10
 male partner pressure over, 110
 nurse role in, 59
- spermatogonia, 1–2
- spondylodiscitis, 55
- SRY* gene. *See* sex-determining region
 on the Y chromosome gene
- standard operating procedures (SOPs),
 58–9, 81–2
- stem cells, oogonial, 2
- stereomicroscope, for oocyte
 preparation, 98–9
- sterilisation, equipment, 38–9, 62
- steroidogenesis, of antral follicles, 4–6
- stigma, 8
- sub-zonal insemination (SUZI), 103
- supplier accreditation, 80–1
- SUZI. *See* sub-zonal insemination
- target controlled infusion (TCI), 30
- temperature control, oocyte, 20–2, 40,
 65, 72, 77–8, 98–9
- tenaculum, 46
- test tubes, for follicular fluid collection,
 20–1, 39–42
- testosterone, 4–6
- theatre space, 18, 22
 air quality of, 21
 anaesthetic room, 19
 design considerations for, 18–19,
 66–8
 equipment and consumables for, 20,
 22
 infection control in, 18–19, 62
 procedure room, 19–21
- theca cells
 of antral follicles, 4–6
 development of, 3–4
- third party agreements, supplier,
 80–1
- 3D ultrasonography, ovarian
 stimulation monitoring with, 11
- thromboprophylaxis, 15
- toxicity testing, of laboratory
 consumables, 71, 79
- traceability, 38, 60, 80, 105,
 109–10
- transabdominal oocyte retrieval, 20, 43,
 47, 52–3
- transfer, from retrieval room to
 laboratory, 66–8
- transgender patient care, 60–1
- transmyometrial oocyte retrieval, 20,
 43, 46, 48, 53
- transport IVF
 laboratory considerations for, 74
 oocyte maintenance during, 102–3
- transvaginal oocyte retrieval (TVOR),
 20. *See also specific topics*
- transvaginal ultrasonography
 OR with, 39–42, 46
 ovarian stimulation monitoring with,
 10–12
- trans-zonal projections (TZPs), 3–4
- trauma, after OR, 15–16
- trigger injection. *See* maturation trigger
 injection
- triptorelin, 14
- tube warmer, validation of, 77–8
- tubing. *See* aspiration tubing
- TVOR. *See* transvaginal oocyte
 retrieval
- TZPs. *See* trans-zonal projections
- u-hCG. *See* urinary hCG
- ultrasonography
 OR with, 39–42, 46–7
 ovarian stimulation monitoring with,
 10–12
- ultrasound scan machine, 20,
 22
 preparation of, 39–40
- ureter, 47–8, 54–5
- urinary hCG (u-hCG), 13–14
- urine pregnancy test, empty follicle
 syndrome and, 46–9
- uterine artery, 43–4, 52–3
- vacuoles, oocyte, 87–8
- vaginal bleeding, 48, 52
- vaginal disinfection, 20, 39,
 53–4
- vaginal ultrasound probe, 39–40
- validation
 equipment and consumables, 70–1,
 77–8
 process, 82
- venous thromboembolism, 15
- verification, laboratory equipment and
 consumables, 70–1
- vertebral injury, 55
- viability, oocyte. *See* oocyte quality
- virus positive patient, 73–4
- visceral injury, 54–5
- vital signs, nurse monitoring of,
 61–3
- volatile organic compounds (VOCs),
 78–9
- well being, patient, 61–2
- WHO. *See* World Health Organisation
- witnessing, 38, 60, 80, 105, 109–10
- Wolffian duct, 1–2
- workstation, optimisation of, 69–70
- World Health Organisation (WHO)
 Guidelines on Hand Hygiene in
 Health Care, 62
 surgical pathway of, 59–60
- zona pellucida (ZP)
 development of, 3–4
 discoloration of, 91
 dysmorphic, 90–1